XOMA (NASDAQ:XOMA) Releases Quarterly Earnings Results

XOMA (NASDAQ:XOMA) released its quarterly earnings results on Monday. The biotechnology company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.17), Zacks reports. XOMA had a negative return on equity of 24.95% and a negative net margin of 151.34%.

XOMA Stock Up 1.4 %

XOMA stock traded up $0.29 during midday trading on Monday, reaching $20.73. The stock had a trading volume of 20,213 shares, compared to its average volume of 26,083. The stock has a market capitalization of $244.26 million, a P/E ratio of -5.96 and a beta of 1.00. The firm’s fifty day simple moving average is $24.85 and its 200-day simple moving average is $27.41. The company has a debt-to-equity ratio of 1.28, a quick ratio of 7.52 and a current ratio of 7.52. XOMA has a 1-year low of $19.92 and a 1-year high of $35.00.

Insiders Place Their Bets

In other XOMA news, major shareholder Bvf Partners L. P/Il sold 500,742 shares of XOMA stock in a transaction on Friday, January 24th. The shares were sold at an average price of $26.10, for a total value of $13,069,366.20. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 7.20% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have commented on XOMA shares. HC Wainwright dropped their target price on shares of XOMA from $123.00 to $104.00 and set a “buy” rating on the stock in a report on Monday, February 3rd. StockNews.com lowered shares of XOMA from a “hold” rating to a “sell” rating in a report on Tuesday, February 25th.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.